Key result
Dapagliflozin lowers the aldosterone-to-renin ratio, risking false-negative primary aldosteronism screens in hypertensive diabetes.
Why the study?
The effects of SGLT-2 inhibitors on the renin-angiotensin-aldosterone system and their correlation with glucose metabolism in T2DM patients with hypertension have not been well studied.
Does dapagliflozin alter renin levels and glucose metabolism in patients with type 2 diabetes mellitus and hypertension?
Cohort (n=147)
No
Does dapagliflozin alter renin levels and glucose metabolism in patients with type 2 diabetes mellitus and hypertension?
Answers are grounded in this paper and cite their sources.
Short-term dapagliflozin therapy in patients with T2DM and hypertension transiently elevates renin levels and reduces the aldosterone-to-renin ratio, which may lead to false-negative screening results for primary aldosteronism.
BACKGROUND: The impact of sodium-glucose cotransporter-2 inhibitors (SGLT-2is), including dapagliflozin, on the renin-angiotensin-aldosterone system (RAAS) in type 2 diabetes mellitus (T2DM) patients remains controversial, as they may either activate or inhibit RAAS, subsequently influencing glucose metabolism and the accuracy of the aldosterone-to-renin ratio (ARR) in diagnosing primary aldosteronism (PA). However, the effects of SGLT-2is therapy on RAAS and their correlation with glucose metabolism have not been well studied. METHODS: A cohort of 147 patients with T2DM and hypertension was prospectively recruited and categorized into two groups: diabetic kidney disease group (DKD, n = 73) and non-DKD group (n = 74), based on diagnostic criteria for diabetic complications. Patients were prescribed 10 mg dapagliflozin daily for 3 months. The primary outcome measure was the change in renin (REN) levels during outpatient visits at baseline, 1 month, and 3 months. The secondary outcome was the change in other metabolic biomarkers from baseline to the 3-month visit. To evaluate the relationship between RAAS components and various glucose metabolism indicators, including HbA1c, FBG, CP, HOMA-β, HOMA-IR, and UACR, Spearman correlation and multiple linear regression analyses were conducted at baseline and 3-month visit. RESULTS: After 3 months, the BMI, HbA1c, FBG, TG, TCHO, SBP, DBP, UACR, and HOMA-IR levels were significantly decreased, while Crea and HOMA-β were significantly increased from the baseline in both groups. Additionally, the differences from the baseline in FBG (-2.64 ± 2.66 vs. -1.70 ± 1.92 mmol/L) and UACR (-355.01 ± 1534.12 vs. -4.66 ± 7.86 mg/g) values were significantly higher in DKD group than those in non-DKD group. REN levels increased significantly from baseline at 1-month visit (4.15 ± 7.35 vs. 2.75 ± 8.03 ng/L; DKD vs. non-DKD; between-group difference, p < 0.05), while ARR values decreased significantly from baseline at 1-month visit (-0.70 ± 1.16 vs. -0.59 ± 1.19; between‑group difference, p > 0.05) and 3-month visit (-0.45 ± 1.15 vs. -0.42 ± 1.07; between‑group difference, p > 0.05) in both groups (within‑group change vs. baseline, p < 0.017). Interestingly, no temporal differences were observed in ALD levels. REN levels returned to baseline after three months of treatment; yet the ARR, which was primarily influenced by REN, remained below its initial value. Multiple linear regression analysis revealed that a 100% increase in Log-ALD was associated with a 0.143 nmol/L higher CP and a 15.8% higher HOMA-IR in DKD group(p < 0.05). A 100% increase in Log-REN was associated with a 0.359 mg/g lower UACR in DKD group and a 0.042 mmol/L higher FBG in non-DKD group(p < 0.01). These correlations were independent of the internal interactions of RAAS but were significantly attenuated after 3 months of treatment. CONCLUSIONS: The correlations between RAAS markers and glucose metabolism indices were significantly attenuated, potentially due to lowered blood glucose levels after SGLT‑2is treatment. However, it is noteworthy that short-term therapy may elevate REN levels and reduce ARR, potentially resulting in false-negative outcomes in PA screening.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2025) conducted a cohort in Type 2 diabetes mellitus with hypertension (n=147). Dapagliflozin vs. Baseline (self-matched) was evaluated on Change in renin (REN) levels from baseline to 1 month and 3 months (p=<0.05). Dapagliflozin treatment significantly increased renin levels at 1 month and persistently reduced the aldosterone-to-renin ratio over 3 months in patients with type 2 diabetes and hypertension, potentially causing false-negative primary aldosteronism screening results.
Synapse has enriched 10 related papers. Consider them for comparative context: